Myths about semen loss and effect of Veeryasthambha vati in Premature ejaculation

Survey of Knowledge of reproductive and sexual health in the community and clinical evaluation of VIRYASTHAMBHA Vati in Premature Ejaculation

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/07/015102

Enrollment

Registered

2018-07-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Premature Ejaculation

Interventions

Intervention1: Veeryasthambha Vati: Ingrediants of the Vati - Jatiphala (Myristica fragrans Houtt.), Lavanga (Syzygium aromaticum (Linn.) Merill and Perry.), Jatipatra (Myristica fragrans Houtt), Kum

Eligibility

Inclusion criteria

Inclusion criteria: Patients complaining of Lifelong PE (Patients complaining of ejaculation occurring too early at nearly every intercourse, from about the first sexual encounter onwards)

Exclusion criteria

Exclusion criteria: 1. Acquired premature ejaculation due to urological dysfunction like prostatitis, thyroid dysfunction etc. (Thyroid function test will be done in clinically suspected cases) 2. Patients having Genito urinary tract infection and showing positive results for VDRL, HIV and HbsAg

Design outcomes

Primary

Measure	Time frame
Trial Drug is effective in increasing the intravaginal ejaculatory latency time (IELT) in premature ejaculationTimepoint: 1 month	—

Secondary

Measure	Time frame
Myths and Misconceptions about reproductive health in the general community (Rural and Urban)will be identifiedTimepoint: 3 years	—

Countries

India

Contacts

Public ContactDr Shivakumar S Harti

KLE University

shivakumarsh@gmail.com9611275434

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026